Singapore Irritable Bowel Syndrome Drugs Market Report 2022 to 2030

Singapore Irritable Bowel Syndrome Drugs Market Analysis

$ 3999

Singapore irritable bowel syndrome drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increased illness awareness, the expected timely availability of recently approved drugs, an enhanced payment system, and rising IBS prevalence are the main market drivers for IBS-D pharmaceuticals. The key players in this market are Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx.

ID: IN10SGPH319 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Netal Patel

Buy Now

Singapore Irritable Bowel Syndrome Drugs Market Analysis Summary

Singapore Irritable Bowel Syndrome Drugs Market is valued at around $2.2 Mn in 2022 and is projected to reach $5.3 Mn by 2030, exhibiting a CAGR of 11.55% during the forecast period 2023-2030.

Colon muscle spasms are a hallmark of irritable bowel syndrome (IBS), a digestive and functional intestinal illness. The large intestine is affected by irritable bowel syndrome. The most prevalent case of irritable bowel syndrome in the elderly is intestinal dysfunction. Target diseases' rising prevalence and the expansion of conventional pharmaceutical labels are both expected to fuel market expansion. In addition, growing medicine use and the launch of new goods are anticipated to drive growth in the irritable bowel syndrome market. Increased illness awareness, the expected timely availability of recently approved drugs, an enhanced payment system, and rising IBS prevalence are the main market drivers for IBS-D pharmaceuticals. The key players in this market are Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx.

Market Dynamics

Market Growth Drivers

Irritable bowel syndrome (IBS), a digestive and functional intestinal disorder, is characterised by colon muscular spasms. Irritable bowel syndrome affects the large intestine. Intestinal dysfunction is the most typical form of irritable bowel syndrome in the elderly. Market expansion is anticipated to be fueled by the increased prevalence of target diseases and the expansion of conventional pharmaceutical labels. In addition, it is projected that rising drug usage and the introduction of new products will fuel market expansion for irritable bowel syndrome.

Market Restraints

Some IBS treatments could come with undesirable or intolerable side effects for some people. These side effects, which can decrease patient compliance and lead to treatment termination, may limit the market potential for some drugs. The process of creating and selling a novel medicine can be costly and time-consuming. Due to the high costs of research, clinical trials, and regulatory approvals, pharmaceutical companies may decide not to invest in the development of IBS medications, leaving patients with fewer new treatment options.

Competitive Landscape

Key Players

Allergan
Ironwood Pharmaceuticals, Inc.
Synergy Pharmaceuticals Inc.
Bausch Health
Takeda Pharmaceutical Company Ltd.
AstraZeneca
Sebela Pharmaceuticals Inc.
Synthetic Biologics, Inc.
Astellas Pharma, Inc.
Ardelyx

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Irritable Bowel Syndrome Drugs Market Segmentation

By Type

IBS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed IBS (IBS-M)

By Products

Rifaximin
Eluxadoline
Linaclotide
Lubiprostone
Others

By End Users

Hospitals
Specialty clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.